The effects of short-term (8 weeks) treatment with three lipid-lowering agents, probucol, pravastatin, and niceritrol on serum lipoprotein (a)[Lp (a)] levels were examined in 82 hypercholesterolemic patients with (43) or without (39) diabetes mellitus (DM) associated with a serum Lp (a) level above 20 mg/d
l.
The mean level of serum Lp (a) was significantly higher in the hypercholesterolemic patients with or without DM than in normolipidemic subjects. The mean level in DM without hyperlipidemia also tended to be high. Probucol and pravastatin significantly decreased serum total cholesterol (TC) and apolipoprotein (apo) B levels in both groups at weeks 4 and 8 as compared to week O, whereas niceritrol also slightly but significantly decreased those of levels. Serum high density lipoprotein-cholesterol was decreased by probucol whereas it was increased by pravastatin. Serum Lp (a) was significantly decreased by niceritrol in non-DM (from 38.7±3.9 mg/d
l at week 0 to 33.3±4.8mg/d
l at week 8, n=15, p<0.01) as well as DM (from 42.6±5.9mg/d
l at week 0 to 33.3±4.8mg/d
l at week 8, n=12, p<0.01), whereas it was increased by pravastain. There was no significant change in serum Lp (a) level with probucol.
These results suggest that combination therapy of probucol and/or pravastatin plus niceritrol may be useful in protecting against the development of diabetic macroangiopathy in diabetic patients with accompanying hypercholesterolemia and high Lp (a) levels.
View full abstract